Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment

Publisher： Karger

E-ISSN： 1423-0232|68|4-6|350-355

ISSN： 0030-2414

Source： Oncology, Vol.68, Iss.4-6, 2005-08, pp. : 350-355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inflammation‐Related Genetic Variations and Survival in Patients With Advanced Non–Small Cell Lung Cancer Receiving First‐Line Chemotherapy

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 360-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 121-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 293-299

Karger

Access to resources Recommend Favorite

Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

Paclitaxel, Epirubicin and Cyclophosphamide Combination in First-Line Treatment of Metastatic Breast Cancer: A Dose Escalation Study

By  

Oncology, Vol. 66, Iss. 3, 2004-06 ,pp. : 185-191

Karger

Access to resources Recommend Favorite